Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.

Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, Ferrone S, Ferris RL.

Clin Cancer Res. 2013 Feb 15;19(4):798-808. doi: 10.1158/1078-0432.CCR-12-1517. Epub 2013 Jan 30.

2.

Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.

Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL.

Cancer Immunol Immunother. 2011 Apr;60(4):525-35. doi: 10.1007/s00262-010-0961-7. Epub 2011 Jan 5.

3.

Immunotherapy for head and neck cancer.

Davidson HC, Leibowitz MS, Lopez-Albaitero A, Ferris RL.

Oral Oncol. 2009 Sep;45(9):747-51. doi: 10.1016/j.oraloncology.2009.02.009. Epub 2009 May 12. Review.

PMID:
19442565
4.

Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists.

Wesa AK, Herrem CJ, Mandic M, Taylor JL, Vasquez C, Kawabe M, Tatsumi T, Leibowitz MS, Finke JH, Bukowski RM, Bruckheimer E, Kinch MS, Storkus WJ.

J Immunol. 2008 Dec 1;181(11):7721-7.

5.

Lack of toxicity of a STAT3 decoy oligonucleotide.

Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP, Li C, Leibowitz MS, Ferris RL, Gooding WE, Thomas SM, Johnson DE, Grandis JR.

Cancer Chemother Pharmacol. 2009 May;63(6):983-95. doi: 10.1007/s00280-008-0823-6. Epub 2008 Sep 3.

6.

Recurrence in head and neck squamous cell carcinoma. Editorial.

Leibowitz MS, Ferris RL.

Cancer. 2008 Aug 15;113(4):671-3. doi: 10.1002/cncr.23616. No abstract available.

7.

Head and neck cancer immunotherapy: clinical evaluation.

Leibowitz MS, Nayak JV, Ferris RL.

Curr Oncol Rep. 2008 Mar;10(2):162-9. Review.

PMID:
18377830
8.

Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer.

Couch ME, Ferris RL, Brennan JA, Koch WM, Jaffee EM, Leibowitz MS, Nepom GT, Erlich HA, Sidransky D.

Clin Cancer Res. 2007 Dec 1;13(23):7199-206.

9.

Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance.

Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, DeMichele A, Schuchter LM, Leibowitz MS, Wexler MH, Vance BA, Beatty GL, Veloso E, Feldman MD, Vonderheide RH.

Cancer Res. 2007 Nov 1;67(21):10546-55.

10.

Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma.

DeLong P, Carroll RG, Henry AC, Tanaka T, Ahmad S, Leibowitz MS, Sterman DH, June CH, Albelda SM, Vonderheide RH.

Cancer Biol Ther. 2005 Mar;4(3):342-6. Epub 2005 Mar 1.

PMID:
15846066

Supplemental Content

Loading ...
Support Center